Abstract Adjuvant therapy may allow patients being that cannot be controlled by other agents, or who require an ACE inhibitor for treatment of heart failure. treated with epoetin to derive greater clinical benefits. Iron supplementation is currently the most widely used
supply to the bone marrow. During the correction Introduction phase, a dose of i.v. iron equivalent to 50 mg/day is recommended, with the total dose not exceeding 3 g.
The potential role of adjuvant therapies in enhancing When subclinical vitamin C deficiency is suspected, the effectiveness of epoetin in chronic renal failure ascorbic acid may be given orally (1-1.5 g/week) or (CRF ) patients has received increasing attention in i.v. (300 mg three times weekly at the end of dialysis). recent years. Adjuvant therapies are important for two The active vitamin D metabolites alfacalcidol and reasons. Firstly, they may help to overcome hypocalcitriol may, under some circumstances, improve responsiveness to epoetin, allowing patients to achieve anaemia and reduce epoetin dosage requirements.
increased haemoglobin concentrations and derive Vitamin B 6 requirements are increased during epoetin greater clinical benefits. Secondly, they may allow therapy, and supplementation at a dose of 100-epoetin to be used more cost-effectively. 150 mg/week is recommended. Supplementation of When haemoglobin does not increase as much as vitamin B 12 is optional. Folic acid is supplemented expected in response to epoetin treatment, the presence routinely in haemodialysis patients, though evidence of either a correctable underlying disorder (such as that it increases the efficacy of epoetin is limited. Low infection or inflammation) or a deficiency state that doses (2-3 mg/week) should normally be sufficient to could be limiting erythropoiesis must be considered. maintain optimal folic acid stores in epoetin-treated
In the last few years, it has become apparent that iron patients, although higher doses are necessary for deficiency is the major cause of hyporesponsiveness to patients with hyperhomocysteinaemia. -Carnitine epoetin, and most institutions are now fully aware that supplementation may be appropriate in some patients the majority of haemodialysis patients receiving epoetin with anaemia of chronic renal failure (CRF ) unrewill also need intravenous (i.v.) iron supplementation. sponsive to, or requiring large doses of, epoetin.
Attention has recently turned towards the usefulness Androgens potentially could reduce epoetin costs in of other adjuvant therapies, including vitamins, horcountries with limited resources, but should only be mones and cytokines. Nutritional status has always used in men older than 50 years with a remnant kidney.
been of concern in patients with CRF; now there is Recent animal studies indicate that the combination increasing awareness that deficiency states may underof epoetin and insulin-like growth factor 1 might be mine the effectiveness of epoetin. Although nutritional beneficial in CRF patients. High doses of angiotensinsupplementation has long been routine practice for converting enzyme (ACE) inhibitors should be patients with CRF, recent research highlights the reserved for dialysis patients who have hypertension specific roles that some vitamins and -carnitine may play in the generation of an ongoing supply of healthy Correspondence and offprint requests to: Professor Dr Dr Walter H. red blood cells. The role of cytokines, both stimulatory converting enzyme (ACE ) inhibitors may adversely affect the response to epoetin.
This review summarizes the workshop Is there a role for adjuvant therapy in patients being treated with epoetin? and presents the recommendations made by the participants on the basis of the available evidence. The answer to the question posed in the workshop title is certainly 'yes'; the challenge for the future is to identify which adjuvant therapies offer the greatest clinical and economic benefits for specific patient groups.
Iron
The response to epoetin is determined primarily by iron availability [1] . In normal circumstances, the major source of iron for erythropoiesis is the iron released from ageing erythrocytes. Any additional iron required is absorbed from the gastrointestinal tract, and iron losses are minimal (0.05% of total body iron). There are no mechanisms (other than blood loss) to Fig. 1 . Condensed algorithm for detecting and managing iron excrete excess iron, and any excess is deposited in the deficiency. reticuloendothelial system as iron stores.
In anaemic patients, however, the amount of circulating iron that is available for new erythropoiesis is diminished and additional iron is required if the hae-least 100 mg/l before epoetin is started; a serum ferritin moglobin concentration is to be increased. For every <100 mg/l should be corrected with i.v. iron. If serum 1 g/dl increase in the haemoglobin concentration, iron ferritin is >200 mg/l at the start of epoetin therapy, equivalent to a serum ferritin concentration of 20 mg/l no immediate iron supplementation is required, is required.
although some nephrologists do continue iron therapy In CRF patients, the supply of iron for the formation until a serum ferritin of 500 mg/l is reached. of new erythrocytes is reduced, due to both blood loss and reduced absorption. One study has reported that nearly three litres of blood may be lost each year Correction phase (500 ml in blood taken for laboratory tests and 2400 ml during dialysis procedures) [2] . There may also be Once epoetin therapy has started, functional iron defiadditional losses through undiagnosed gastrointestinal ciency may occur (i.e. demand may exceed the capacity bleeding. Absorption of iron via the gastrointestinal of the reticuloendothelial stores to release the required mucosa has been shown to be diminished in both amount of iron), even when iron stores are adequate haemodialysis and peritoneal dialysis patients [3] . In (serum ferritin >200 mg/l ). In this situation, there is addition, many patients are treated with drugs that reduced movement of iron from the diminished labile impair iron absorption.
iron pool to the developing erythroblasts, which gives The appropriate use of iron supplementation is, rise to hypochromic red blood cells (red cells with a therefore, an important key to successful epoetin haemoglobin concentration <28 g/dl ). Hypochromic therapy. Intravenous iron is more effective than oral red cells are a hallmark of functional iron deficiency, iron in increasing erythropoiesis and reducing the and their measurement is the most direct way of epoetin dose required in haemodialysis patients [4] , assessing whether or not iron supply to the responding and the i.v. route is now firmly established as the marrow is adequate [7] . When the proportion of preferred route of iron administration in this patient hypochromic red cells exceeds 10%, i.v. iron is required. group [5, 6 ] .
A transferrin saturation of <12% also indicates the Both absolute and functional iron deficiency may be need for i.v. iron therapy. observed in haemodialysis patients receiving epoetin.
Whereas the daily iron requirement for new haemo-A condensed algorithm for detecting and managing globin synthesis is only~30 mg in normal subjects, both types of iron deficiency in patients receiving erythropoietic activity will typically double with epoeepoetin therapy is shown in Figure 1 . Iron management tin therapy. The iron deficit will usually be may be divided into three phases: pre-epoetin phase,~5 0 mg/day. The amount of i.v. iron required should correction phase and maintenance phase.
be calculated on this basis, and the total dose given during the correction phase should not exceed 3 g.
Pre-epoetin phase
Levels in excess of 3 g will result in an increasing proportion of the dose being deposited in the iron Evidence of absolute iron deficiency should be sought in the pre-epoetin phase. Serum ferritin should be at stores.
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Maintenance phase the study (four control and eight ascorbic acid-treated patients). There is evidence to show that i.v. iron leads to a
The results showed that 13 of the remaining 27 further stimulation of erythropoiesis and an increase ascorbic acid-treated patients had a good response, in haemoglobin in iron-replete individuals with a stable with a dramatic rise in haematocrit (25.8±1.7% vs haemoglobin and epoetin dose [4, 6, 8] . Additional iron 30.4±2.1%, P<0.05) and a concomitant 20% reducmay therefore allow further bone marrow production, tion in epoetin dose after 8 weeks. The enhancement thereby providing extra benefit. The increase in mean in erythropoiesis paralleled a rise in transferrin saturacorpuscular volume seen with iron therapy in patients tion, from 28.4±11.2% to 47.9±19%, and a fall in with excess iron stores provides indirect evidence for erythrocyte ZnPP, from 123±45 mmol/mol haem to this hypothesis [9] .
70±13 mmol/mol haem (P<0.05). In poor responders However, in order to protect patients from possible (14/27) and in controls (n=15), there were no significiron overload, iron therapy should be stopped when ant changes in mean epoetin dose, or mean haematothe proportion of hypochromic red cells declines to crit, transferrin saturation or ZnPP values. <10%, when transferrin saturation exceeds 40% or
The 42 patients who completed the study were when serum ferritin reaches 600-1000 mg/l. stratified further into groups of those who did (n=13) In some continuous ambulatory peritoneal dialysis and those who did not (n=29) require i.v. ascorbic and pre-dialysis iron-replete patients, who do not have acid. Receiver operator curves showed that two indices the same degree of blood loss as dialysis patients, oral predicted response to i.v. ascorbic acid supplemeniron supplementation may be sufficient during the tation: erythrocyte ZnPP >90 mmol/mol haem and maintenance phase. However, even in these patients, transferrin saturation <25%. The authors concluded careful monitoring for signs of iron-deficient erythro-that when epoetin hyporesponsiveness occurs in poiesis (hypochromic red cells, reticulocyte indices) haemodialysis patients with iron overload, the above may indicate a need for i.v. iron.
values should be used to guide treatment with i.v. ascorbic acid. Tarng and Huang have also compared the effects of
Vitamin C
i.v. iron administration with those of i.v. ascorbic acid in 50 epoetin-resistant haemodialysis patients with serum ferritin >500 mg/l [14] . Patients were allocated Haemodialysis may be associated with subclinical vitamin C deficiency, and some nephrologists recom-to one of two protocols: (i) i.v. iron sucrose 100 mg×5 doses (n=15) vs controls (n=11); or (ii) i.v. ascorbic mend routine vitamin C supplementation for dialysis patients, whether or not they are receiving epoetin. acid 300 mg three times weekly for 8 weeks (n=12) vs controls (n=12). Oral doses of ascorbic acid are usually in the range of 50-200 mg/day, though some authors recommend Short-term i.v. iron supplementation in these patients neither improved erythropoiesis nor reduced higher doses [10] .
Recently, it has been shown that i.v. ascorbic acid epoetin doses. In contrast, i.v. ascorbic acid led to a significant increase in haematocrit ( Figure 2 ) and a administration can overcome resistance to epoetin in patients who have functional iron deficiency, even reduction in the requirement for epoetin.
On the basis of the available data, the workshop when they are iron overloaded [11, 12] . Tarng and Huang treated 12 epoetin-resistant, iron-overloaded recommended that when subclinical vitamin C deficiency is suspected, CRF patients not on dialysis patients with ascorbic acid (300 mg i.v. post-dialysis three times weekly) [12] . After 8 weeks of treatment, should receive oral ascorbic acid 1-1.5 g/week; haemodialysis patients should receive the same regimen, or the haematocrit had increased significantly, with a concomitant significant rise in transferrin saturation, i.v. ascorbic acid 300 mg three times weekly at the end of dialysis. and a decrease in zinc protoporphyrin (ZnPP). Monthly doses of epoetin were also significantly There are concerns that, in the long term, high doses of ascorbic acid could lead to oxalate accumulation reduced. Possible explanations for this effect of ascorbic acid include increased iron absorption, mobilization [15] . However, preliminary data suggest that this potential hazard can be prevented by avoiding of iron from inert tissue stores, and increased iron utilization in the erythron [13] .
vitamin B 6 deficiency [15] . To determine whether there are any indices that can predict which patients will require i.v. ascorbic acid Vitamin D therapy, Tarng et al. studied 54 iron-overloaded patients (serum ferritin >500 mg/l ) [13] . The treatment group (n=35) comprised patients hyporesponsive to Secondary hyperparathyroidism (HPT ) can aggravate anaemia in patients on haemodialysis. Furthermore, it epoetin, who received ascorbic acid 300 mg three times weekly for 8 weeks. Controls (n=19) had a haematocrit has been found that the dose of epoetin required to achieve an adequate increase in haemoglobin is related of >30% and did not receive the adjuvant therapy. Red blood cell and iron metabolism indices and eryth-to the severity of secondary HPT and, in particular, to the extent of bone marrow fibrosis [16 ] . rocyte ZnPP were measured before therapy and after 8 weeks. Twelve patients had withdrawn by the end of Before the advent of epoetin, it was shown that patients was 811 pg/ml at entry, indicating significant secondary HPT. Patients were treated with calcitriol (2 mg i.v. after dialysis, adjusted according to PTH, serum calcium and phosphate levels). After 12 months of treatment, 19 patients were classified as responders, i.e. PTH had decreased. These patients showed a significant increase in mean haemoglobin from 10.6±1.5 g/dl to 12.2±1.5 g/dl (P<0.001). The increase in haemoglobin in response to calcitriol was correlated with a significant decrease in PTH. These findings raise an interesting question: does the effect of active vitamin D metabolites on haemoglobin reflect solely the correction of HPT, or could there also be direct effects on erythroid precursor cells in the bone marrow? The hypothesis that there may be direct effects is supported by two findings. Firstly, calcitriol can induce the proliferation and maturation of stem cells in vitro [23] . Secondly, calcitriol treatment in vivo can improve anaemia in some patients, even if it does not lower PTH, without alterations to epoetin dosage [21, 24, 25] . Further evidence is needed, however, before vitamin D metabolites can be recommended as adjuvant treatments in patients without evidence of HPT.
Vitamin B 6
, vitamin B 12 and folic acid
Deficiencies in vitamin B 12 and folic acid are rare in pre-dialysis patients [26 ] . However, in both peritoneal doses and i.v. ascorbic acid 300 mg three times weekly for 8 weeks in patients with functional iron deficiency and serum ferritin dialysis and haemodialysis patients, folic acid and >500 mg/l, vs controls. It appears that i.v. ascorbic acid can over-vitamins B 6 and B 12 can be lost in the dialysate, come resistance to epoetin in these patients. (Reproduced with especially during high-flux dialysis. This is because permission from [14] ).
these vitamins are water-soluble and of small-tomedium molecular size [27] . Supplementation of folic parathyroidectomy could lead to an increase in haemo-acid and vitamins B 6 and B 12 is therefore current globin in anaemic patients with secondary HPT practice in many dialysis units, and usually results in [17] . Subsequently, it has also been shown that normal or higher than normal plasma values. parathyroidectomy can increase haematocrit, serum immunoreactive erythropoietin and reticulocytes in patients receiving epoetin [18] .
Vitamin B 6 Similarly, medical treatment of secondary HPT with the active vitamin D metabolites calcitriol or alfacal-Vitamin B 6 is involved in haem synthesis and in the incorporation of iron into haem, and is important as cidol improves the anaemia of CRF, in both epoetintreated and untreated patients [19] [20] [21] [22] . In some cases, a co-factor in erythropoiesis. Severe vitamin B 6 deficiency may occur in patients with CRF as a result of it has been found that the administration of alfacalcidol or calcitriol allows a reduction in the dose of epoetin restricted diet, impaired metabolism of the active form (pyridoxyl-5-pyrophosphate) and losses in either the [20, 21] .
Albitar et al. administered oral alfacalcidol urine (from frusemide administration) or the dialysate. However, studies of vitamin B 6 status in patients with 6-7 mg/week for 12 months to 12 haemodialysis patients. The patients had previously been on epoetin CRF have yielded contradictory results, probably due to methodological discrepancies. therapy for at least 6 months, and still had a haemoglobin of <10 g/dl [19] . Epoetin was discontinued at Recently, a vitamin B 6 deficiency in erythrocytes has been reported in both peritoneal dialysis patients and least 1 month prior to the study. The mean haemoglobin increased from 8.7±1.2 g/dl at baseline to haemodialysis patients receiving epoetin, despite normal plasma concentrations [28] . The study data 10.3±0.8 g/dl at 3 months (P<0.05 vs baseline), after which it remained stable as long as alfacalcidol therapy suggest that vitamin B 6 requirements are increased in patients receiving epoetin therapy and that a vitamin B 6 was continued.
Goicoechea et al. studied 28 haemodialysis patients, deficiency may lead to resistance to the hormone. Vitamin B 6 supplementation at a dose of 100-21 of whom were receiving epoetin [21] . The mean plasma parathyroid hormone (PTH ) level in these 150 mg/week is therefore considered advisable.
Vitamin B
12 -Carnitine deficiency is believed to be a key factor underlying some of these processes. -Carnitine is Vitamin B 12 deficiency has been reported only once an important carrier molecule in the transport of long-[29]; nonetheless, there may be a long-term risk of chain fatty acids across the inner mitochondrial memdeficiency due to losses in the dialysate, especially with brane for beta-oxidation, and it appears to be importhigh-flux membranes. If and when vitamin B 12 defi-ant for membrane phospholipid metabolism. In ciency occurs, it is likely to be a late event, as the liver addition, -carnitine is responsible for regulating the stores contain enough of the vitamin to last for 3-5 concentration of co-enzyme A (CoA) and for removing years. Supplementation of vitamin B 12 may be regarded the toxic acyl-CoAs that accumulate in CRF patients as optional; when it is given, a dose of 0.25 mg/month due to incomplete oxidation. Deficiency of -carnitine should be sufficient. Tielemans et al. (unpublished leads to accumulation of toxic acyl-CoAs and low data) found that, with i.v. supplementation of erythrocyte membrane sodium/potassium ATPase vitamin B 12 0.5 mg/month, patients on high-flux activity. dialysis maintained a greater than normal plasma -Carnitine is dialysable, and is depleted from the concentration throughout a 5 year follow-up period.
muscle stores during long-term haemodialysis. Patients on dialysis tend to have reduced free plasma carnitine Folic acid and markedly elevated plasma acyl carnitine (AC ), leading to a higher than normal AC to free carnitine Folic acid supplementation has been advocated on the ( FC ) ratio (AC5FC >0.4). The total plasma carnitine, basis of a single 30-year-old publication [30] . However, however, may be normal or elevated, depending on as today's diets are less restricted, losses of folic acid the amount of AC. in the dialysate have less impact. Consequently, the Patients with CRF also appear to have abnormal need for routine supplementation in both epoetin-and renal handling of carnitine [35] . There may be reduced non-epoetin-treated patients is now being questioned, mitochondrial carnitine palmityl-transferase activity in [31] .
the heart and skeletal muscle of uraemic patients, Nonetheless, there is some evidence that folic acid which may result in reduced carnitine action. demand may be increased in epoetin-treated patients.
The symptoms of -carnitine deficiency include Pronai et al. [32] have reported the development of unexplained lethargy, muscular weakness, hypotenhyporesponsiveness to epoetin therapy, together with sion, cardiac dysfunction and arrhythmias, and recurmacrocytic anaemia, despite initially normal plasma rent cramps. It is often difficult to distinguish the folic acid levels. Response to epoetin increased and above from similar symptoms related to uraemia and mean cell volume decreased in eight patients given dialysis. folic acid supplementation (10 mg/day).
Some authors have advocated -carnitine Low doses (2-3 mg/week) should normally be supplementation in an attempt to alleviate symptoms sufficient to maintain optimal folic acid stores in related to -carnitine deficiency. In non-epoetin-treated epoetin-treated patients, although higher doses are haemodialysis patients, administration of -carnitine necessary for patients with hyperhomocysteinaemia.
has been reported to increase haematocrit, correct lipid However, the workshop participants noted that high abnormalities and improve muscular and cardiac funcdoses of folic acid (15 mg/day) may increase the risk tion [35] . of thromboembolic events [33] . When assessing folic Moreover, several studies have shown that -carniacid stores, erythrocyte folic acid levels are preferable tine administration improves the response to epoetin to serum levels.
[34,36,37], and a correlation has been seen between Preliminary findings by Sunder-Plassmann et al.
the epoetin dosage required and total plasma carnitine (unpublished) suggest that high-dose folate therapy [38] . In a placebo-controlled study, Labonia et al. has no beneficial effect on epoetin responsiveness in found that i.v. -carnitine supplementation for 6 CRF patients with hyperhomocysteinaemia, despite months led to a 38% reduction in epoetin dosage [36 ] . the finding that elevated total homocysteine concentraHowever, it should be borne in mind that studies of tions in end-stage renal failure patients can be partially the effects of -carnitine supplementation have included corrected by folic acid.
only small numbers of patients, have lacked sufficient controls and have shown both responders and non--Carnitine responders. The mechanisms responsible for a possible effect of -carnitine have not yet been elucidated. However, an Although inadequate secretion of erythropoietin is the critical defect in the anaemia of CRF, shortened improvement in erythrocyte sodium/potassium ATPase activity has been reported during -carnitine erythrocyte survival may also be important. In uraemia, erythrocyte survival time may be reduced due administration [39] . -Carnitine may also help to stabilize reticulocyte membranes through the adeto increased erythrocyte ATP (secondary to decreased sodium/potassium ATPase activity and stimulated quate supply of fatty acids, resulting in improved survival of mature red blood cells. glycolysis), alterations in lipid and phospholipid membrane components and impairment of the pentoseIn the study by Labonia et al., there was no detectable change in red blood cell globular osmotic fragility phosphate shunt [34] . and endogenous erythropoietin secretion before and 24.4% at baseline to 32.9%, P<0.001 vs epoetin alone).
No side effects of nandrolone decanoate were noted after -carnitine supplementation [36 ] . However, a study by Matsumura et al. confirmed a correlation during this short-term study.
In a longer-term study by Gaughan et al. in 11 men between epoetin dosage and free carnitine concentrations, and demonstrated increased red blood cell globu-and eight women on haemodialysis, patients received epoetin 1500 IU three times weekly for 6 months, with lar osmotic fragility in patients with a low -carnitine level [40] . Administration of -carnitine has also been or without the addition of nandrolone decanoate, 100 mg i.m. weekly [44] . At the end of the study, both shown to reduce erythrocyte membrane fragility in dialysed patients [37] .
groups showed a significant increase in mean haematocrit compared with baseline, but the increase in the In summary, there is some evidence to support the notion that administration of -carnitine to haemo-androgen-treated group was significantly greater than in the group receiving epoetin alone (8.2% vs 3.5%, dialysis patients may improve anaemia and, in turn, reduce epoetin requirements. However, placebo-P=0.012, Figure 3) [44]. No side effects of nandrolone decanoate were noted in this study, except for pain at controlled studies that carefully control for other parameters influencing erythropoiesis are needed the injection site.
Other studies, by Teruel et al., have examined the before definitive conclusions can be drawn.
A recent consensus group statement [41] concluded erythropoietic effect of androgen therapy given alone in patients with CRF [45] [46] [47] . In the largest of these that -carnitine supplementation in dialysis patients should not be routine. This strategy should be reserved studies, which included 67 men and 17 women, there was a significant age-related erythropoietic effect of only for patients with certain conditions, including the anaemia of CRF unresponsive to, or requiring large i.m. nandrolone decanoate (200 mg weekly for 6 months). Treatment was associated with an increase in doses of, epoetin. Patients with elevated PTH or C-reactive protein (CRP), as well as those with alumi-dry weight and serum albumin, a reversible increase in serum triglycerides, and a decrease in lipoprotein(a); nium toxicity or megaloblastosis, should not be treated with -carnitine. As there are currently only limited there was no change in prostate tumour markers or blood pressure. Most women receiving nandrolone data in this area, a pragmatic approach should be adopted. A trial supplementation period may be indi-decanoate experienced mild hirsutism and voice change. The authors noted that these side effects were cated to exclude -carnitine deficiency as the cause of epoetin resistance or unresponsiveness in selected significant disadvantages to treatment.
Even in men, there is concern about negative effects patients.
of androgens on the liver and prostate. In the study described above, Teruel et al. found elevations in liver Androgens enzymes in three patients with antibodies to hepatitis C, which returned to normal when androgen treatment was stopped. However, none of the 13 patients with Before the introduction of epoetin, studies had already been conducted on the efficacy of androgens in treating biochemical data indicative of liver disease experienced a worsening of the disease during treatment [47] . In the anaemia of CRF. Androgens are believed to improve erythropoiesis either via their ability to another study of 14 men receiving nandrolone decanoate 200 mg i.m. weekly for 6 months, androgen adminincrease endogenous erythropoietin production from the remnant kidney or by enhancing the sensitivity of erythroid progenitors to available erythropoietin [42] .
Since the introduction of epoetin, several studies have examined the potential role of androgens in enhancing response and reducing dose requirements. One 16 week study in 12 men and five women found that intramuscular (i.m.) nandrolone decanoate 2 mg/kg/week plus i.v. epoetin 120 IU/kg/week had no greater effect than epoetin alone [43] . Two patients receiving nandrolone decanoate in this study were withdrawn because of acne.
However, two other studies have shown a significantly greater increase in haematocrit with i.m. nandrolone decanoate than with epoetin alone. In a study by Ballal et al., 15 adult male haemodialysis patients were given epoetin 2000 IU three times weekly, with or without the addition of 100 mg nandrolone decanoate i.m. each week [42] . After 12 weeks of therapy, there istration did not induce increases in prostatic tumour adults treated with recombinant human growth hormone (rhGH ), there was an increase in erythropoiesis, markers [45] . Nevertheless, at present, it seems prudent to recommend that the use of androgens as an adjunct-together with an increase in total blood volume and total body water [53] . It was shown that rhGH had ive therapy to epoetin be restricted to men older than 50 years with a remnant kidney.
increased serum IGF-1 but not serum erythropoietin. It was therefore hypothesized that growth hormone It is possible that androgens could be useful in combination with epoetin in countries where resources and IGF-1 may have direct effects on erythroid and myeloid progenitor precursor cells. In children of short are limited. The workshop recommended that a prospective, randomized study be conducted in both pre-stature who were treated with rhGH, blood haemodialysis and dialysis patients to compare low-dose s.c. globin was shown to correlate positively with relative epoetin with low-dose epoetin plus nandrolone decano-body height, serum IGF-1 and IGF-binding protein-3 ate in order to assess whether adjuvant therapy with but not with serum erythropoietin [54] . Similarly, a androgens is cost-effective. study in uraemic patients with severe HPT has shown that haematocrit correlates better with serum IGF-1 than with serum erythropoietin [55] .
Cytokines
Recent unpublished data have also shown that anaemia in dialysis patients is modulated by changes in their IGF-1-binding protein concentrations. Cytokines may either promote or inhibit erythroFurthermore, the erythrocytosis that occurs following poiesis. There may be a role for stimulatory cytokines renal transplantation has been found to be due to an as adjuvant therapy with epoetin, while detection of abnormality of IGF-1 and its binding proteins [56 ] . inhibitory cytokines may help to assess the reasons for These findings led to the suggestion that IGF-1 hyporesponsiveness to epoetin. might be useful as an adjuvant to epoetin in the treatment of the anaemia of CRF. In a murine model, IGF-1 mice with surgically induced renal failure were treated Insulin-like growth factor 1 (IGF-1) was first described for 3 weeks with subtherapeutic doses of epoetin, in 1982 as a new candidate for the regulation of IGF-1, or the combination. Neither agent alone caused erythropoiesis [48] . IGF-1 receptors are found on any significant change in haemoglobin [57] . However, erythrocyte precursors and mature erythrocytes, and it the combination produced a striking increase in haemois thought that growth hormone can stimulate erythro-globin, resulting in correction of anaemia in the majorpoiesis via IGF-1.
ity of animals ( Figure 4 ) [57] . The response to This 'somatomedin hypothesis' is supported by a combination therapy was comparable with that seen study of hypophysectomized rats [49] , which demon-with the maximal dose of epoetin in a dose-finding strated that IGF-1 can stimulate erythropoiesis both study. These data suggest that the combination of directly and indirectly. Growth arrest in hypophysecto-epoetin and IGF-1 might be beneficial in CRF patients, mized rats not only results in low levels of IGF-1, but also in reduced erythropoiesis. Administration of IGF-1 led to an increase in the rate of erythropoiesis and an increase in serum erythropoietin. However, it was found that the stimulatory effect on erythropoiesis occurred before the increase in serum erythropoietin. Thus, IGF-1 may have both an endocrine and a paracrine mechanism of action. The role played by locally produced IGF-binding proteins has yet to be elucidated, however.
At the cellular level, it is known that both IGF-1 and erythropoietin decrease apoptosis of human erythroid colony-forming cells [50] . Erythropoietin also maintains erythroid cell viability and development, whereas IGF-1 enhances erythroid maturation and proliferation. However, the proliferation of erythroid progenitors is controlled mainly by stem cell factor (SCF ) and erythropoietin, independent of an effect on apoptosis. Interferon-c down-regulates the number of SCF and erythropoietin receptors on erythroid colonyforming cells, but not IGF-1 receptors [51] .
In rats, there is evidence that IGF-1 and not erythro- growth [52] . It is interesting to note that erythropoiesis treatment alone had any effect on haemoglobin, the combination is impaired in adult patients with growth hormone resulted in a significant increase (P<0.05 vs the other treatments).
(Reproduced with permission from [57] ).
deficiency. In a study of growth hormone-deficient A role for adjuvant therapy in patients treated with epoetin 57 and human studies are now required to test this hypothesis.
IL-3
Various other cytokines are thought to enhance erythroid cell proliferation and maturation, including interleukin-3 (IL-3), IL-4, IL-9, IL-11, SCF and granulocyte-macrophage colony-stimulating factor (GM-CSF ). It has been suggested that a decrease in stimulatory cytokines, such as IL-3, is a cause of epoetin resistance [58] .
In erythropoiesis, IL-3 is an early active cytokine, and IL-3 and GM-CSF receptors share a common beta-chain. Both cytokines enhance erythropoietindependent erythropoiesis in vitro by primary haematopoietic progenitor and factor-dependent cells. There is evidence that the beta-chain functionally and physically associates with the erythropoietin receptor, suggesting that these cytokine receptors exist as a large super- for the synergistic effects of IL-3 and GM-CSF with erythropoietin during erythropoiesis.
IL-3 has been shown to increase the number of ACE inhibitors and response to epoetin colonies derived from burst-forming units-erythroid (BFU-E) and colony-forming units-granulocyte Anaemia sometimes occurs as a side effect of ACE macrophage (CFU-GM ) grown in the presence of inhibitors given to treat hypertension [65] or heart erythropoietin in vitro [59] . One in vitro study took failure. Studies of patients with renal insufficiency [66 ] BFU-E from patients with renal anaemia 2 weeks after and renal transplant patients [67] also indicate that the start of epoetin therapy. An increase in growth of the anaemia of CRF is aggravated by ACE inhibitors. BFU-E was seen when IL-3 was added to the culture In 27 enalapril-treated patients with CRF, Kamper medium, indicating an enhanced sensitivity of BFU-E et al. [66 ] found that haemoglobin declined over 90 to IL-3 [60] . Another in vitro study in renal patients days from a median of 7.6 mmol/l to 6.7 mmol/l; in a demonstrated that the addition of erythroid differenti-control group of 32 patients haemoglobin remained ation factor, either alone or in combination with IL-3, constant at 7.6 mmol/l (P<0.001 enalapril vs control ). improved a reduced sensitivity of BFU-E to epoetin Moreover, in the enalapril-treated group, the median [61] . Finally, an analysis of circulating haematopoietic erythropoietin concentration declined from 32 to progenitors in haemodialysis patients showed that 24 IU/l, whereas it remained unchanged in control sensitivity of peripheral blood BFU-E to IL-3 was patients (P<0.05 enalapril vs control ). lower in patients with a poor response to epoetin Vlahakos et al. reviewed 27 transplant patients treatment [62] .
treated with enalapril and found that 37% had Many studies have investigated the potential of IL-3 developed an otherwise unexplained anaemia [67] . to treat different states of bone marrow failure and Julian et al. have also reported that administration haematological malignancies, and to expand haemato-of ACE inhibitors to post-transplant patients may poietic progenitor cells for transplantation. However, suppress erythropoiesis [68] . no clinical use for IL-3 has been established to date There is evidence linking the rate of secretion of [63] .
endogenous erythropoietin in haemodialysis patients to activation of the renin-angiotensin system. When Inhibitory cytokines this system is inhibited, erythropoietin secretion decreases. In one study in haemodialysis patients, Recently, Bárány et al. have reported that increased serum CRP is a strong predictor of resistance to captopril (50 mg) given prior to a dialysis session completely blocked the expected increase in serum epoetin, suggesting increases in inflammatory cytokines ( Figure 5) [64]. Epoetin dosage and serum CRP were erythropoietin [69] .
ACE inhibitors have also been found to markedly both inversely correlated with serum albumin and serum iron. These data suggest that the principal increase the plasma natural stem cell regulator Nacetyl-seryl-aspartyl-lysyl-proline (Ac-SDKP). An mechanism by which inflammatory cytokines inhibit erythropoiesis is linked to iron metabolism (i.e. func-increase in Ac-SDKP may cause anaemia by preventing the recruitment of pluripotent haematopoietic tional iron deficiency). CRP testing must be included among routine blood tests in haemodialysis patients, stem cells and normal early progenitors into S-phase [70] . assisting the early detection and treatment of epoetin resistance.
A recent study by Morrone et al. [71] suggests that $ Intravenous iron therapy is required by most haemodialysis patients receiving epoetin. Folic acid demand may be increased by epoetin conflicting findings is that the dose of both epoetin treatment, though the evidence for the efficacy and the ACE inhibitor is important. It may be that a of supplementation is equivocal. Low doses reduced response to epoetin is seen only when the (2-3 mg/week) should normally be sufficient, ACE inhibitor is given at a high dose and epoetin at although higher doses are necessary for patients a relatively low dose. When the opposite is true, no with hyperhomocysteinaemia. effect may be seen. patients; however, patients with elevated PTH or normotensive controls [74] . A mean haemoglobin con-CRP, as well as those with aluminium toxicity or centration of >10 g/dl was maintained in all groups. megaloblastosis, should be excluded. The mean weekly epoetin dose increased in the enala-$ Androgens in combination with epoetin could be pril group (P<0.0001 vs baseline) and remained conuseful in countries where resources are limited. stant in the nifedipine and control groups ( Figure 6 ) However, androgen use should be confined to men [74] . The authors of this study concluded that higholder than 50 years with a remnant kidney. dose enalapril increased epoetin requirements. This $ Recent animal studies strongly suggest that the implies that high-dose ACE inhibitors should be combination of epoetin and IGF-1 might be benereserved for dialysis patients whose hypertension ficial in CRF patients. Human studies are now cannot be controlled by other agents, or patients who required to test this hypothesis. require an ACE inhibitor for treatment of heart failure.
$
High serum CRP indicates high levels of inflammatory cytokines, and is a strong predictor of Conclusions resistance to epoetin. In future, routine testing for CRP could assist in the early detection and treatment of epoetin resistance. In summary, the conclusions of this workshop are as follows. Nephrol Dial Transplant 1994; 9: 1027 an ACE inhibitor for treatment of heart failure. 

High doses of ACE inhibitors should be reserved
A role for adjuvant therapy in patients treated with epoetin 59 22. Albitar S, Meulders Q, Soutif C et al. High-dose 1a-vitamin D for dialysis patients whose hypertension cannot be improves anaemia in haemodialysed population in the absence controlled by other agents, or patients who require of erythropoietin.
